# US Liquid Biopsy Market

> US Liquid Biopsy Market Research Report: Size, Share, Trend Analysis By Typess (Circulating Tumor Cells, Circulating Tumor DNA, Extracellular Vesicles, Others), By Applications (Cancer Therapeutic Application, Reproductive Health, Others) and By Sample (Blood Sample, Urine Sample, Other) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 10.52%
- **2024:** $ 2,547.72 Million
- **2025:** $ 2,815.74 Million
- **2035:** $ 7,656.04 Million
- **Key Players:** Guardant Health (US), Exact Sciences (US), GRAIL (US), Freenome (US), Biocept (US), Foundation Medicine (US), Roche (CH), Thermo Fisher Scientific (US), Illumina (US)

**Report ID:** MRFR/HC/11817-HCR · **Pages:** 100 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-liquid-biopsy-market-13342

---

## Market Summary

## **US Liquid Biopsy Market Overview**

**As per MRFR analysis, the US Liquid Biopsy Market Size was estimated at 2.31 (USD Billion) in 2023. The US Liquid Biopsy Market Industry is expected to grow from 2.55(USD Billion) in 2024 to 8.03 (USD Billion) by 2035. The US Liquid Biopsy Market CAGR (growth rate) is expected to be around 10.999% during the forecast period (2025 - 2035).**

### **Key US Liquid Biopsy Market Trends Highlighted**

The US Liquid Biopsy Market is witnessing significant growth, driven by a rising demand for non-invasive diagnostic solutions. As more healthcare professionals and patients seek early detection and monitoring of cancer, the ability of liquid biopsies to detect circulating tumor DNA and other biomarkers provides a compelling alternative to traditional tissue biopsies. Moreover, advancements in genomic technologies and an increase in research funding from government agencies are contributing to the development and validation of innovative liquid biopsy tests.

Opportunities in the US market are expanding as regulatory bodies, such as the FDA, provide clearer guidelines for the approval of [liquid biopsy](../../../reports/liquid-biopsy-market-710) tests, paving the way for new products to enter the market. The growing prevalence of cancer and the necessity for personalized medicine further enhance the potential for liquid biopsy adoption in clinical practice. Additionally, the integration of liquid biopsy tests into routine healthcare workflows presents a chance for healthcare providers to improve patient outcomes and streamline diagnostic processes.

In recent times, collaborations and partnerships between biotech firms and academic institutions are on the rise, facilitating the sharing of knowledge and technology in the development of liquid biopsy solutions. The increasing interest in precision medicine has also led to an uptick in clinical trials focusing on liquid biopsies, promoting innovation and efficacy. As patients become more aware of liquid biopsy options, the market is likely to experience increased acceptance, aligning with the broader trend of patient-centric healthcare in the US.

Overall, these trends indicate a dynamic and rapidly evolving landscape for liquid biopsies in the United States, underscoring their potential impact on cancer diagnostics and management.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **US Liquid Biopsy Market Drivers**

#### **Increasing Incidence of Cancer Cases**

The US has seen a notable rise in cancer cases, with the American Cancer Society reporting approximately 1.9 million new cancer cases diagnosed in 2021 alone. This rising prevalence of cancer drives the demand for innovative diagnostic methods like liquid biopsies. As the US Liquid Biopsy Market Industry evolves, major institutions such as the National Cancer Institute and the American Society of Clinical Oncology are recognizing the importance of liquid biopsies for early detection and monitoring of cancer.

Moreover, the United States government is increasing funding for research and development related to cancer diagnostics, which enhances the scope for liquid biopsy technologies across the nation. This upward trend in cancer cases and government backing provides a strong impetus for the growth of the US Liquid Biopsy Market Industry.

#### **Technological Advancements in Liquid Biopsy Solutions**

Technological advancements have significantly improved the efficiency and accuracy of liquid biopsy techniques, such as circulating tumor DNA (ctDNA) analysis. Organizations like Guardant Health and Foundation Medicine are at the forefront, developing cutting-edge liquid biopsy solutions that allow for non-invasive cancer diagnostics. These advancements are influenced by increased funding for Research and Development from both private and public sectors.

A report by the National Institutes of Health indicates that federal funding for genomic and personalized medicine initiatives has grown substantially, enhancing the capabilities of liquid biopsies. This focus on innovation bolsters the US Liquid Biopsy Market Industry, encouraging more healthcare providers to adopt these state-of-the-art diagnostic methods.

#### **Rising Awareness and Adoption of Minimally Invasive Procedures**

There is a growing awareness and preference for minimally invasive diagnostic methods amongst patients and healthcare providers. Liquid biopsies offer a less painful alternative to traditional biopsies, thus appealing to patients who prioritize patient comfort. Healthcare providers in the US are increasingly promoting liquid biopsies as a viable option for cancer monitoring and detection, with organizations like the American Society of Clinical Oncology endorsing their use.

The National Cancer Institute states that patient preference for non-invasive procedures has increased by over 25% in recent years, reflecting a wider trend towards non-invasive techniques in the healthcare industry. This shift in patient preferences supports the future growth of the US Liquid Biopsy Market Industry.

#### **Supportive Regulatory Framework**

The regulatory landscape in the US has become increasingly supportive towards the development and commercialization of liquid biopsies. The Food and Drug Administration has introduced frameworks that expedite the approval process for innovative diagnostic tests. This is evident from the FDA’s Breakthrough Devices Program, which aids in accelerating the development of technologies that may provide more effective treatment or diagnosis. As per FDA announcements, the approval of liquid biopsy products has more than doubled over the last five years.

This supportive framework is crucial for companies looking to enter the US Liquid Biopsy Market Industry, allowing them to bring their solutions to the market faster and more efficiently.

### **US Liquid Biopsy Market Segment Insights**

#### **Liquid Biopsy Market Types Insights**

The US Liquid Biopsy Market is witnessing significant growth due to its non-invasive approach to cancer diagnostics, as it allows for early detection and monitoring of cancer through the analysis of biological fluids. The market can be categorized based on Types, which include Circulating Tumor Cells, Circulating Tumor DNA, Extracellular Vesicles, and Others. Circulating Tumor Cells have emerged as a pivotal tool for understanding cancer metastasis and treatment responses, enabling oncologists to tailor therapies based on real-time information.

Circulating Tumor DNA holds substantial relevance as it provides insights into tumor genetics from a simple blood draw, facilitating personalized medicine strategies by tracking mutations and therapeutic resistance without the need for invasive biopsies. Extracellular Vesicles, which carry proteins and nucleic acids, play an essential role as biomarkers for various cancers and are increasingly recognized for their ability to provide information about a tumor's microenvironment, aiding in the identification of aggressive cancers.

Furthermore, the "Others" category encompasses a variety of additional biomarkers and methodologies made possible by advancements in molecular biology and technology, which are contributing to the diversification of liquid biopsy applications.

Factors driving growth in the US Liquid Biopsy Market include a rising prevalence of cancer, continual advancements in technology that enhance sensitivity and specificity, and a shift towards precision medicine. However, challenges such as regulatory hurdles and reimbursement issues remain prevalent, while opportunities lie in expanding research collaborations and increasing awareness among healthcare providers. Overall, the diversification within the Types segment reflects the potential for innovation that can significantly impact cancer diagnostics and patient management in the US healthcare landscape.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

#### **Liquid Biopsy Market Application Insights**

The Application segment of the US Liquid Biopsy Market plays a critical role in the healthcare landscape, driven by increasing adoption in Cancer Therapeutic Application and Reproductive Health. The Cancer Therapeutic Application dominates this market due to the rising prevalence of various cancers among the population, leading to a growing demand for innovative and non-invasive diagnostic tools that enhance personalized treatment options. Reproductive Health also holds significant importance, offering valuable insights into genetic disorders and pregnancy-related conditions, thereby facilitating early intervention strategies.

Other applications within this segment further broaden the utility of liquid biopsies, addressing a variety of health concerns. As the US government prioritizes precision medicine, advancements in liquid biopsy technology are expected to lead to greater patient outcomes, fueling market growth. The increasing focus on minimally invasive procedures aligns with patient preferences, creating opportunities for expansion across different healthcare settings. Overall, the rich landscape of applications in the liquid biopsy sector presents valuable opportunities for healthcare providers aiming to improve diagnostic accuracy and patient management.

#### **Liquid Biopsy Market Sample Insights**

The US Liquid Biopsy Market is experiencing significant growth, particularly within the Sample segment which includes Blood Samples, Urine Samples, and Other biological fluids. Blood Samples are crucial as they offer a non-invasive method for detecting cancer biomarkers, making them the most widely utilized option among clinicians and researchers. Urine Samples are also gaining traction due to their ease of collection and the potential to detect a range of conditions, providing a viable alternative for patients who may prefer less invasive procedures.

The Other segment encompasses various bodily fluids that can be analyzed, such as saliva, which is emerging as a promising avenue for liquid biopsy applications. The rising prevalence of cancer and increasing demand for early detection methods are pivotal drivers influencing this market segment. Moreover, advancements in technology and regulatory support further enhance accessibility and adoption of these liquid biopsy approaches. Therefore, the diverse applications and benefits of these different sample types make them integral to the overall landscape of the US Liquid Biopsy Market, fostering continuous innovation and growth in the industry.

### **US Liquid Biopsy Market Key Players and Competitive Insights**

The US Liquid Biopsy Market has experienced significant growth over the past few years, driven by advancements in technology and increasing demand for non-invasive diagnostics in oncology. This competitive landscape is characterized by numerous players offering innovative solutions that allow for the detection of cancer-related biomarkers through blood samples. The focus on personalized medicine and targeted therapies has further propelled interest and investment in liquid biopsies, making it a vital segment within the diagnostic industry. Companies are increasingly enhancing their product offerings and forming strategic collaborations to foster innovation and improve testing accuracy, thereby intensifying the competition.

As players strive to capture greater market share, the emphasis on regulatory approvals and clinical validations becomes crucial in establishing trust and credibility in the market.

Foundation Medicine, operating within the US Liquid Biopsy Market, has established a strong foothold thanks to its innovative genomic profiling solutions that aid in precision medicine. The company leverages its proprietary technology to analyze tumor DNA from blood samples, enabling oncologists to make informed treatment decisions tailored to individual patients. Foundation Medicine’s strengths lie in its comprehensive test offerings and collaborations with both pharmaceutical companies and diagnostic laboratories, which enhance its market presence. Furthermore, their focus on expanding access to their tests through partnerships and reimbursement strategies has solidified their position in the industry.

The company is well-regarded for its dedication to advancing cancer care through its precision diagnostics, fostering an ecosystem that promotes heightened awareness and utilization of liquid biopsy technologies.

Sysmex Inostics, a significant player in the US Liquid Biopsy Market, delivers crucial products and services that focus on cancer diagnostics through liquid biopsy technologies. Their key offerings include specialized genetic testing that provides insights into tumor mutations and their potential response to therapies. Sysmex Inostics’ strengths lie in its advanced testing technologies and meaningful collaborations with healthcare providers that enable efficient integration of their solutions in clinical practice. The company actively engages in research and development efforts, ensuring that its products are at the forefront of innovation in the liquid biopsy space.

They have made strategic moves including mergers and acquisitions to enhance their capabilities, expand their product portfolio, and strengthen their competitive position in the market. Their commitment to providing high-quality diagnostic services tailored to the US market enhances their presence and operational efficiency in this rapidly evolving landscape.

### **Key Companies in the US Liquid Biopsy Market Include**

### **US Liquid Biopsy Market Industry Developments**

Recent developments in the US Liquid Biopsy Market have been marked by significant advancements and strategic movements among key players. Foundation Medicine launched its new liquid biopsy test, enhancing genomic profiling capabilities. Sysmex Inostics, focused on cancer diagnostics, continues to innovate through cutting-edge technologies. In August 2023, Guardant Health announced a collaboration with another prominent firm to enhance its precision oncology offerings. A notable merger occurred in September 2023, when Freenome acquired a subsidiary of Biocept to expand its testing capabilities and operational footprint.

The market is currently valued at several billion USD, with projections indicating substantial growth driven by increasing adoption of non-invasive diagnostics.

Regulatory approvals by the FDA for innovative liquid biopsy tests have also spurred confidence in this market, with a focus on improving patient outcomes through early cancer detection. Other companies such as GRAIL and Natera are actively developing new assays, contributing to the dynamic landscape of the US Liquid Biopsy Market, which has seen rapid evolution and increasing investments over the past few years.

### **US Liquid Biopsy Market Segmentation Insights**

#### **Liquid Biopsy Market Types Outlook**

#### **Liquid Biopsy Market Application Outlook**

#### **Liquid Biopsy Market Sample Outlook**

- Blood Sample
- Urine Sample
- Other

## Market Drivers

### Rising Incidence of Cancer

The increasing incidence of cancer in the US is a primary driver for the liquid biopsy market. According to the American Cancer Society, approximately 1.9 million new cancer cases are expected to be diagnosed in 2025. This alarming statistic underscores the urgent need for innovative diagnostic tools. Liquid biopsies offer a non-invasive alternative to traditional tissue biopsies, enabling earlier detection and monitoring of cancer progression. As healthcare providers seek to improve patient outcomes, the demand for liquid biopsy solutions is likely to rise. The liquid biopsy market is poised to benefit from this trend, as it aligns with the growing emphasis on personalized medicine and targeted therapies.

### Expansion of Biomarker Research

The expansion of biomarker research is a crucial factor propelling the liquid biopsy market. As researchers identify new biomarkers associated with various diseases, the potential applications for liquid biopsies continue to grow. This trend is particularly evident in oncology, where liquid biopsies are being developed to detect specific tumor markers. The liquid biopsy market is benefiting from collaborations between academic institutions and biotechnology companies, leading to innovative product development. With an estimated 30% increase in biomarker discovery initiatives in 2025, the market is likely to experience significant growth as these advancements translate into clinical applications.

### Technological Innovations in Diagnostics

Technological advancements in diagnostic tools are significantly influencing the liquid biopsy market. Innovations such as next-generation sequencing (NGS) and digital PCR are enhancing the sensitivity and specificity of liquid biopsies. These technologies allow for the detection of minimal residual disease and genetic mutations with greater accuracy. The liquid biopsy market is experiencing a surge in research and development activities, with investments reaching approximately $1.5 billion in 2025. This influx of funding is expected to accelerate the introduction of novel liquid biopsy products, thereby expanding the market and improving patient care.

### Increased Focus on Early Disease Detection

The heightened focus on early disease detection is significantly impacting the liquid biopsy market. Early diagnosis is critical for improving treatment outcomes, particularly in cancer care. Liquid biopsies facilitate the detection of circulating tumor DNA and other biomarkers at earlier stages of disease progression. The liquid biopsy market is responding to this demand by developing tests that can be integrated into routine screening protocols. As healthcare systems prioritize preventive care, the market is expected to grow, with projections indicating a potential market value of $5 billion by 2027. This emphasis on early detection aligns with broader public health initiatives aimed at reducing mortality rates.

### Growing Demand for Minimally Invasive Procedures

The increasing preference for minimally invasive procedures is driving the liquid biopsy market. Patients and healthcare providers alike are recognizing the benefits of non-invasive testing methods, which reduce recovery time and associated risks. Liquid biopsies, which utilize blood samples, align with this trend by offering a safer alternative to traditional biopsies. The liquid biopsy market is likely to see a substantial increase in adoption rates, as studies indicate that over 70% of patients prefer non-invasive testing options. This shift in patient preference is expected to propel market growth in the coming years.

## Future Outlook

The [Liquid Biopsy Market](https://www.marketresearchfuture.com/reports/liquid-biopsy-market-710) is projected to grow at a 10.52% CAGR from 2025 to 2035, driven by technological advancements, increasing cancer prevalence, and demand for non-invasive diagnostics.

**New opportunities:**

- Development of AI-driven analytics platforms for enhanced diagnostic accuracy.
- 
- Expansion of liquid biopsy applications in early-stage cancer detection.
- Partnerships with healthcare providers for integrated testing solutions.

By 2035, the liquid biopsy market is expected to achieve substantial growth, positioning itself as a cornerstone of modern diagnostics.

## Segment Insights

### By Application: Cancer Diagnosis (Largest) vs. Treatment Monitoring (Fastest-Growing)

In the US liquid biopsy market, the application segment showcases a diverse landscape, with Cancer Diagnosis accounting for the largest share. Following closely are Treatment Monitoring and Recurrence Monitoring, while Clinical Trials and Research Applications contribute to the market in smaller proportions. This distribution highlights the importance of accurate and early cancer detection, which drives a significant portion of liquid biopsy adoption across healthcare facilities in the region.

Analyzing growth trends, Treatment Monitoring is recognized as the fastest-growing application due to increasing emphasis on personalized medicine and ongoing advancements in biomarker identification. Moreover, the rise in cancer prevalence in the US underscores the importance of ongoing monitoring for effective treatment strategies. This dynamic landscape emphasizes continuous innovation and the integration of technological feats in liquid biopsy applications, ultimately fostering improved patient outcomes and healthcare efficiency.

Application: Cancer Diagnosis (Dominant) vs. Recurrence Monitoring (Emerging)

Cancer Diagnosis stands as the dominant application in the US liquid biopsy market, serving a crucial role in facilitating non-invasive testing for early cancer detection. Through the detection of circulating tumor DNA, this application not only enhances diagnostic accuracy but also significantly streamlines the patient experience by reducing the need for invasive procedures. On the other hand, Recurrence Monitoring is emerging as a critical area of focus as it supports ongoing surveillance post-treatment to detect any possible cancer relapse. This growing emphasis on recurrence monitoring reflects a shift towards more proactive patient management strategies, which aim to enhance long-term survival rates and improve overall patient care.

### By Sample Type: Blood (Largest) vs. Urine (Fastest-Growing)

In the US liquid biopsy market, the blood sample type holds the largest market share, attributed to its established use in cancer diagnostics and monitoring. Blood-based assays are favored for their minimally invasive nature and ability to provide comprehensive insights into circulating tumor DNA, making it a critical component for early detection and treatment planning.

Conversely, the urine sample segment is rapidly gaining traction, positioning itself as the fastest-growing segment. This growth is propelled by advancements in technology and increasing awareness of the non-invasive advantages of urine tests. Additionally, the rising prevalence of urological cancers contributes to the heightened demand for urine-based liquid biopsies in clinical settings.

Blood (Dominant) vs. Urine (Emerging)

Blood samples represent a dominant force in the US liquid biopsy market, primarily due to their high sensitivity and the wealth of information they can provide regarding tumor dynamics. They are extensively utilized in the detection of various cancers and offer clinicians critical insights into patient prognosis and treatment efficacy. On the other hand, urine samples are emerging as a valuable alternative, driven by their non-invasive collection method and lower patient discomfort. Urine-based tests are particularly advantageous for monitoring specific cancers and have gained popularity in research settings, further positioning them as a feasible option in clinical diagnostics.

### By Technology: Next Generation Sequencing (Largest) vs. Digital PCR (Fastest-Growing)

In the US liquid biopsy market, Next Generation Sequencing (NGS) leads the technology segment, exhibiting the largest market share due to its advanced capabilities in detecting genetic variations and mutations. Digital PCR follows as a vital technology, rapidly gaining traction amongst researchers and clinical laboratories for its precision and reliability in quantifying nucleic acids.

The growth of the technology segment is primarily driven by the increasing demand for non-invasive diagnostic methods and personalized medicine. Technological advancements, such as automation and improved accuracy in detecting biomarkers, further propel market expansion. Additionally, a rising incidence of cancer and other diseases necessitating precise diagnostics has resulted in heightened investment in liquid biopsy technology, making it a focal point in the healthcare landscape.

Technology: Next Generation Sequencing (Dominant) vs. Digital PCR (Emerging)

Next Generation Sequencing (NGS) is a dominant player in the US liquid biopsy market, characterized by its ability to analyze multiple genes simultaneously, offering comprehensive insights into genetic mutations. Its efficiency in sequencing has established it as a preferred method among oncologists and researchers. In contrast, Digital PCR represents an emerging technology with a growing reputation for its exceptional sensitivity in quantifying low abundance biomarkers. While NGS is typically used for extensive genomic analysis, Digital PCR stands out for its precision and the ability to provide quantitative results in a more streamlined process. Together, these technologies enhance diagnostic capabilities and patient management in oncology.

### By End Use: Diagnostic Laboratories (Largest) vs. Hospitals (Fastest-Growing)

In the US liquid biopsy market, the distribution of market share among the end-use segments reveals Diagnostic Laboratories as the largest contributor, capitalizing on their extensive infrastructure and capabilities for advanced testing. Hospitals follow closely, benefiting from their integrated healthcare services and the increasing prevalence of chronic diseases driving the demand for liquid biopsy procedures. Research Institutes and Pharmaceutical Companies constitute smaller but crucial segments, focusing on innovative applications and clinical trials that ultimately enhance the market landscape.

The growth trends in the US liquid biopsy market are prominently marked by the rapid expansion of the Hospitals segment, driven by technological advancements and a shift towards personalized medicine. The rising incidence of cancer and genetic disorders fuels demand for liquid biopsies in diagnostics and treatment monitoring. Additionally, the increasing investment in healthcare infrastructure and the push for early detection methods contribute to this segment's strong growth, positioning Hospitals at the forefront of liquid biopsy utilization.

Diagnostic Laboratories (Dominant) vs. Hospitals (Emerging)

Diagnostic Laboratories are the dominant force in the US liquid biopsy market, characterized by their specialization in advanced molecular testing and established protocols that ensure accurate results. They are equipped with cutting-edge technologies, enabling them to perform a variety of assays efficiently. On the other hand, the Hospitals segment, while emerging, showcases rapid growth due to a rising focus on comprehensive patient care and the integration of liquid biopsy tests into routine clinical workflows. The combination of direct patient interaction and the ability to offer immediate diagnostic results positions Hospitals as a pivotal player, responding swiftly to patient needs and driving innovation in liquid biopsy applications.

## Competitive Benchmarking

The[liquid biopsy market](https://www.marketresearchfuture.com/reports/gene-editing-market-707) is currently characterized by a dynamic competitive landscape, driven by advancements in technology and increasing demand for non-invasive diagnostic solutions. Key players such as Guardant Health (US), Exact Sciences (US), and GRAIL (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. Guardant Health (US) focuses on innovation in genomic profiling, aiming to provide comprehensive insights into cancer treatment. Meanwhile, Exact Sciences (US) emphasizes partnerships with healthcare providers to expand its reach and improve patient access to its testing solutions. GRAIL (US) is leveraging its expertise in early cancer detection, positioning itself as a leader in the development of multi-cancer early detection tests, which collectively shapes a competitive environment that is increasingly reliant on technological advancements and strategic collaborations.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for market share while also collaborating through strategic partnerships. This collective influence of key players fosters a competitive atmosphere where innovation and operational efficiency are paramount.
In October Guardant Health (US) announced a strategic partnership with a leading healthcare provider to enhance the integration of its liquid biopsy tests into routine clinical practice. This collaboration is expected to facilitate broader access to advanced genomic testing, thereby potentially increasing patient enrollment in clinical trials and improving treatment outcomes. Such partnerships are crucial as they not only expand market reach but also reinforce the importance of integrating cutting-edge diagnostics into standard care protocols.
In September Exact Sciences (US) launched a new liquid biopsy test aimed at improving the accuracy of colorectal cancer detection. This introduction is significant as it underscores the company's commitment to innovation and its focus on addressing unmet clinical needs. By enhancing the sensitivity and specificity of its tests, Exact Sciences (US) is likely to strengthen its competitive position in a market that increasingly values precision medicine.
In August GRAIL (US) secured a substantial investment to accelerate the development of its multi-cancer early detection tests. This funding is pivotal as it enables GRAIL (US) to expand its research capabilities and expedite the commercialization of its innovative solutions. The emphasis on early detection aligns with broader trends in oncology, where early intervention is critical for improving patient outcomes.
As of November current competitive trends in the liquid biopsy market are heavily influenced by digitalization, sustainability, and the integration of artificial intelligence (AI) into diagnostic processes. Strategic alliances are increasingly shaping the landscape, allowing companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological innovation, reliability of supply chains, and the ability to deliver personalized healthcare solutions. This shift indicates a market poised for transformation, where the emphasis will be on enhancing patient outcomes through advanced diagnostic capabilities.

## Recent News & Developments

Recent developments in the US Liquid Biopsy Market have been marked by significant advancements and strategic movements among key players. Foundation Medicine launched its new liquid biopsy test, enhancing genomic profiling capabilities. Sysmex Inostics, focused on cancer diagnostics, continues to innovate through cutting-edge technologies. In August 2023, Guardant Health announced a collaboration with another prominent firm to enhance its precision oncology offerings. A notable merger occurred in September 2023, when Freenome acquired a subsidiary of Biocept to expand its testing capabilities and operational footprint.

The market is currently valued at several billion USD, with projections indicating substantial growth driven by increasing adoption of non-invasive diagnostics.

Regulatory approvals by the FDA for innovative liquid biopsy tests have also spurred confidence in this market, with a focus on improving patient outcomes through early cancer detection. Other companies such as GRAIL and Natera are actively developing new assays, contributing to the dynamic landscape of the US Liquid Biopsy Market, which has seen rapid evolution and increasing investments over the past few years.

## Report Scope

| MARKET SIZE 2024 | 2547.72(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 2815.74(USD Million) |
| MARKET SIZE 2035 | 7656.04(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.52% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Guardant Health (US), Exact Sciences (US), GRAIL (US), Freenome (US), Biocept (US), Foundation Medicine (US), Roche (CH), Thermo Fisher Scientific (US), Illumina (US) |
| Segments Covered | Application, Sample Type, Technology, End Use |
| Key Market Opportunities | Advancements in non-invasive cancer diagnostics drive growth in the liquid biopsy market. |
| Key Market Dynamics | Technological advancements and regulatory support drive growth in the liquid biopsy market, enhancing diagnostic capabilities. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US liquid biopsy market as of 2024?**
A: The US liquid biopsy market was valued at $2547.72 Million in 2024.

**Q: What is the projected market valuation for the US liquid biopsy market in 2035?**
A: The projected valuation for the US liquid biopsy market in 2035 is $7656.04 Million.

**Q: What is the expected CAGR for the US liquid biopsy market during the forecast period 2025 - 2035?**
A: The expected CAGR for the US liquid biopsy market during the forecast period 2025 - 2035 is 10.52%.

**Q: Which application segment holds the highest valuation in the US liquid biopsy market?**
A: The Cancer Diagnosis application segment held the highest valuation at $1010 Million in 2024, projected to reach $3050 Million by 2035.

**Q: What are the key sample types utilized in the US liquid biopsy market?**
A: The key sample types include Blood, Urine, Saliva, Pleural Fluid, and Cerebrospinal Fluid, with Blood leading at $1010 Million in 2024.

**Q: Which technology segment is expected to show significant growth in the US liquid biopsy market?**
A: Next Generation Sequencing is expected to show significant growth, with a valuation of $800 Million in 2024, projected to reach $2400 Million by 2035.

**Q: Who are the leading players in the US liquid biopsy market?**
A: Key players in the US liquid biopsy market include Guardant Health, Exact Sciences, GRAIL, Freenome, and Foundation Medicine.

**Q: What is the projected growth for the Treatment Monitoring segment in the US liquid biopsy market?**
A: The Treatment Monitoring segment was valued at $700 Million in 2024 and is projected to grow to $2100 Million by 2035.

**Q: How does the end-use segment of hospitals compare to diagnostic laboratories in the US liquid biopsy market?**
A: In 2024, hospitals were valued at $1018 Million, while diagnostic laboratories were valued at $764 Million, indicating hospitals' leading position.

**Q: What is the expected growth trajectory for the Recurrence Monitoring segment in the US liquid biopsy market?**
A: The Recurrence Monitoring segment was valued at $400 Million in 2024 and is projected to reach $1200 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-liquid-biopsy-market-13342*